NMRA vs PALI

Neumora Therapeutics, Inc. vs Palisade Bio, Inc. — Valuation Comparison 2026

NMRA

Biological Products, (No Diagnostic Substances)
Neumora Therapeutics, Inc.
Quality
3.8
out of 10
Value Trap
30
LOW
Price
$1.85
Last close
Models
7/13
Active
VS

PALI

Biological Products, (No Diagnostic Substances)
Palisade Bio, Inc.
Quality
4.0
out of 10
Value Trap
27
LOW
Price
$2.12
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NMRA Fair ValueNMRA Upside PALI Fair ValuePALI Upside
Bayesian DCF Intrinsic $0.78 -57.9% $0.91 -56.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.55 -16.1% $0.86 -59.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NMRA vs PALI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NMRA vs PALI — Which Stock Is More Undervalued?

PALI scores higher with a 4.0/10 quality rating vs NMRA's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Neumora Therapeutics, Inc. (NMRA) and Palisade Bio, Inc. (PALI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NMRA currently trades at $1.85 with a QOC of 3.8/10, while PALI trades at $2.12 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).